BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38711136)

  • 1. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study.
    Poiraud C; Lenne X; Bruandet A; Theis D; Bertrand N; Turpin A; Truant S; El Amrani M
    World J Surg Oncol; 2024 May; 22(1):123. PubMed ID: 38711136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.
    Bergeat D; Turrini O; Courtin-Tanguy L; Truant S; Darnis B; Delpero JR; Mabrut JY; Regenet N; Sulpice L
    Langenbecks Arch Surg; 2018 Sep; 403(6):701-709. PubMed ID: 30112638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis.
    Mackay TM; Smits FJ; Roos D; Bonsing BA; Bosscha K; Busch OR; Creemers GJ; van Dam RM; van Eijck CHJ; Gerhards MF; de Groot JWB; Groot Koerkamp B; Haj Mohammad N; van der Harst E; de Hingh IHJT; Homs MYV; Kazemier G; Liem MSL; de Meijer VE; Molenaar IQ; Nieuwenhuijs VB; van Santvoort HC; van der Schelling GP; Stommel MWJ; Ten Tije AJ; de Vos-Geelen J; Wit F; Wilmink JW; van Laarhoven HWM; Besselink MG;
    HPB (Oxford); 2020 Feb; 22(2):233-240. PubMed ID: 31439478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Okada K; Takahashi S; Sueda T
    J Surg Oncol; 2018 Dec; 118(7):1105-1114. PubMed ID: 29878355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
    Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious complications of pancreatoduodenectomy correlate with lower rates of adjuvant chemotherapy: Results from the recurrence after Whipple's (RAW) study.
    Russell TB; Labib PL; Ausania F; Pando E; Roberts KJ; Kausar A; Mavroeidis VK; Marangoni G; Thomasset SC; Frampton AE; Lykoudis P; Maglione M; Alhaboob N; Bari H; Smith AM; Spalding D; Srinivasan P; Davidson BR; Bhogal RH; Croagh D; Dominguez I; Thakkar R; Gomez D; Silva MA; Lapolla P; Mingoli A; Porcu A; Shah NS; Hamady ZZR; Al-Sarrieh B; Serrablo A; ; ; ; ; ; ; ; ; Aroori S
    Eur J Surg Oncol; 2023 Sep; 49(9):106919. PubMed ID: 37330348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience.
    Xia BT; Ahmad SA; Al Humaidi AH; Hanseman DJ; Ethun CG; Maithel SK; Kooby DA; Salem A; Cho CS; Weber SM; Stocker SJ; Talamonti MS; Bentrem DJ; Abbott DE
    Ann Surg Oncol; 2017 Sep; 24(9):2770-2776. PubMed ID: 28600732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
    Matsumoto I; Tanaka M; Shirakawa S; Shinzeki M; Toyama H; Asari S; Goto T; Yamashita H; Ishida J; Ajiki T; Fukumoto T; Shimokawa M; Ku Y
    Ann Surg Oncol; 2015 Jul; 22(7):2408-15. PubMed ID: 25487967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yamaue H
    Eur J Surg Oncol; 2021 Oct; 47(10):2586-2594. PubMed ID: 34127329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
    Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA
    World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
    Valle JW; Palmer D; Jackson R; Cox T; Neoptolemos JP; Ghaneh P; Rawcliffe CL; Bassi C; Stocken DD; Cunningham D; O'Reilly D; Goldstein D; Robinson BA; Karapetis C; Scarfe A; Lacaine F; Sand J; Izbicki JR; Mayerle J; Dervenis C; Oláh A; Butturini G; Lind PA; Middleton MR; Anthoney A; Sumpter K; Carter R; Büchler MW
    J Clin Oncol; 2014 Feb; 32(6):504-12. PubMed ID: 24419109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Ohge H; Sueda T
    J Gastrointest Surg; 2009 Jan; 13(1):85-92. PubMed ID: 18704593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy.
    Watanabe Y; Shinkawa T; Endo S; Abe Y; Nishihara K; Nakano T
    World J Surg; 2018 Aug; 42(8):2617-2626. PubMed ID: 29383429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
    Horowitz DP; Hsu CC; Wang J; Makary MA; Winter JM; Robinson R; Schulick RD; Cameron JL; Pawlik TM; Herman JM
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1391-7. PubMed ID: 20643511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
    de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
    Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.